2020 American Transplant Congress
Remote Steroid Wean is Safe When Compared to Early Wean in Heart Transplant Recipients
Cardiovascular Disease, Heart Failure and Transplant, Houston Methodist Hospital, Houston, TX
*Purpose: The risks and benefits of remote steroid wean in heart transplant recipients is unknown. We compared outcomes in patients undergoing early and remote steroid…2020 American Transplant Congress
Sirolimus Combined with Low-Dose Calcineurin Inhibitor in Kidney Transplant Recipients from Expanded Criteria Donors
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: To evaluate the efficacy and safety of conversion from calcineurin inhibitor-based immunosuppressive regimen to sirolimus combined with low-dose calcineurin inhibitor in recipients with abnormal…2020 American Transplant Congress
T Cell Hyporesponsiveness in Kidney Transplant Recipients is Associated with Urinary Tract Infections and Age of Kidney Transplant: Implications for Allograft Nephropathy
Dept of Nephrology, University of KwaZulu-Natal, Durban, South Africa
*Purpose: Chronic allograft nephropathy is the main cause of kidney graft loss. With the use of potent immunosuppressive treatments, acute rejections are less and less…2020 American Transplant Congress
Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression During the First Year Post-Transplant (<1yr Tx) Increases Risk for CMV Infection Through Inhibition of Anti-CMV Humoral Immunity
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have shown a higer CMV infection rate in kidney Tx patients (KTx Pts) who were converted to BLT 1yr post-Tx. Viral infections are…2020 American Transplant Congress
Development and Cell Surface Testing of a Novel Nanofiber Technology for Targeted Delivery of Therapeutic Regulatory T Cells
*Purpose: Regulatory CD4+CD25+FOXP3+ T cells (Tregs) have been shown to induce tolerance in transplantation models, and to be increased in their numbers in tolerant human…2020 American Transplant Congress
2-Year Results of a Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients
*Purpose: In December 2015, our center instituted a protocol change moving to de novo use of tacrolimus-XR (LCPT). The objective of this extension study is…2020 American Transplant Congress
Prospective, Randomized Study of Conversion from Calcineurin Inhibitor (CNI)- to Belatacept (BELA)-Based Maintenance Immunosuppression in Renal Transplant Recipients
*Purpose: CNIs are associated with adverse systemic and nephrotoxic effects that negatively impact long-term patient and graft survival. In a phase 2 study, switching renal…2020 American Transplant Congress
The Impact of Purposeful Reductions in Immunosuppression on Clinical Outcomes in Kidney Transplantation
*Purpose: Reductions to immunosuppressive therapy (IS) are often made due to infection or other IS intolerances, but little is known of impact of these reductions…2020 American Transplant Congress
Assessing Immunosuppression with Immunological Testing and Surveillance Biopsies Late after Liver and Intestine Transplantation (LT, IT)
Pediatric Transplant, Pittsburgh, PA
*Purpose: Assessing adequacy of immunosuppression is essential during late allograft surveillance after LT or IT.*Methods: To explain why allograft function tests can be normal despite…2020 American Transplant Congress
Preventing Allograft Rejection by Circrna FSCN1 Mediated Tolerogenic Dendritic Cells
Pathology, University of Western Ontario-LHSC, London, ON, Canada
*Purpose: Induction of immune tolerance is a major challenge in heart transplants. There is no robust treatment with fewer side effects for preventing chronic rejection.…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 138
- Next Page »